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ABSTRACT 
Objectives: Mucocutaneous leishmaniasis is widely distributed 
in Brazil, with Leishmania (Mannia) braziliensis being the major 
etiologic agent. The currently recommended therapy is limited by 
its parenteral use, high toxicity, and variable efficacy. A clinical pilot 
study was conducted to analyze itraconazole as an oral alter- 
native for the treatment of mucocutaneous leishmaniasis. 
Methods: Ten patients were enrolled to receive 4 mg/kg per day 
(up to 400 mg/d) itraconazole for 6 weeks on an outpatient 
regimen. Diagnosis was based on clinical otorhinolaryngologic 
examination, followed by a specific serologic reaction, the Mon- 
tenegro test and pathologic analysis with immunohistochemi- 
cal reaction. Healing of the lesions was confirmed by clinical 
otorhinolatyngologic examination. Side effects were monitored 
by general clinical assessment, hemoglobin determination, 
leukocyte counts, and liver function tests, all performed before, 
during, and 1 month after the end of treatment. 
Results: Six of 10 patients presented healed lesions 3 months 
after treatment, with a sustained therapeutic response for at 
least a median period of 14.5 months (range, 12-I 8 mo). Side 
effects were not observed. 
Conclusions: This pilot study demonstrated that itraconazole 
can be an effective and well-tolerated alternative for the treat- 
ment of mucocutaneous leishmaniasis. Further randomized 
studies and double blind controlled trials are needed to assess 
the benefits of this drug in the treatment of mucocutaneous 
leishmaniasis. 
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Leishmaniasis is a disease that illustrates the extent to 
which human action in the transformation of ecosys- 
tems can result in human disease. What previously was 
a cycle without human participation has now become a 
human disease in several regions of the world. A total of 
12 million cases has been estimated worldwide, with 
increasing numbers in periurban regions.’ In Brazil, 
approximately 200 thousand cases of American tegu- 
mentary leishmaniasis (ATL) and 23 thousand cases of 
visceral leishmaniasis have been reported between 1980 
and 1993.2 
Specifically concerning ATL in Brazil, the most preva- 
lent species of infecting agents are Leishmania (Leish- 
mania) amazonensis, Leishmania viannia guyanensis, 
and Leishmania viannia braziliensis, whereas the vec- 
tors are sandflies of the genera Lutzomyia and Psy- 
chodopygus. Particularly important is L. viannia 
braziliensis, present in all regions of the country and 
causing the mucocutaneous form of the disease.2,’ 
In the Americas, ATL occurs in three clinical forms: 
cutaneous, diffuse cutaneous, and mucocutaneous. In 
mucocutaneous leishmaniasis (MCL), after a period of 
incubation of 15 to 60 days, a pruriginous nodule arises 
that progresses to a round or oval, large and shallow ulcer 
with raised borders, purplish in color, and only slightly 
painful. One or several lesions may occur. Spontaneous 
cure of cutaneous lesions has been reported in the liter- 
ature.4 Involvement of the mucosa of the nasopharynx, 
oropharynx, larynx, or trachea is a complication that may 
cause destruction of tissues, difficulty in eating because 
of dysphagia, or even tracheomalacia, with patient death 
occasionally occurring due to aspiration or respiratory 
obstruction.5 
Pentavalent antimonials are the drugs of preference 
for the treatment of ATL, although their effectiveness is 
limited in MCL, and they sometimes have significant tox- 
icity and side effects.” Pentamidine and amphotericin B 
are alternative drugs commonly recommended; however, 
they may have significant side effects and also require 
parenteral administration.’ Among the other drugs used 
for the treatment of MCL are liposomal amphotericin, 
aminosidine sulfate, and the combination of allopurinol 
and interferon-gamma with antimonials.8-11 
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A drug administered orally, with lower toxicity and 
adequate to the epidemiologic reality of MCL, would be 
of considerable benefit. There has been a growing inter- 
est in imidazoles; additionally, the anti-leishmania action 
of ketoconazole has been demonstrated in vitro.‘* Encour- 
aged by the clinical results obtained with the cutaneous 
form, in the present study, the authors investigated the 
oral use of itraconazole for the treatment of MCL, a pro- 
cedure that, it is believed, previously has not been 
applied. l3 
PATIENTS AND METHODS 
Patients 
Ten patients with MCL were followed-up at the Special- 
ized ATL Outpatient Clinic, Section of Infectious and Par- 
asitic Diseases, University Hospital, Faculty of Medicine, 
University of SPo Paulo. Data concerning to sex, age, and 
symptoms were obtained from these patients. Each 
patient gave written consent to participate in the study 
after being informed in detail about the study and its pos- 
sible benefits and side effects. The study was approved 
by the Ethics and Research Committees of the Depart- 
ment of Infectious and Parasitic Diseases of the Faculty 
of Medicine, University of Slo Paulo. The inclusion cri- 
terion was a diagnosis of MCL based on the parameters 
described below. The exclusion criteria were pregnancy, 
the use of any medication for the treatment of MCL dur- 
ing the previous 6 months, and transaminase alterations. 
Diagnosis 
Diagnosis was based on clinical otorhinolaryngologic 
evaluation performed by the same specialist to determine 
the presence of hyperemia, edema, granulation, or septal 
perforation with an inflammatory aspect on its borders, 
using indirect or direct laryngoscopy and fibroscopic 
examination when necessary. The Montenegro skin test 
and serologic reaction by indirect immunofluorescence 
were applied. Material obtained from a biopsy of the 
lesions was submitted to anatomopathologic examina- 
tion, after staining by hematoxylin-eosin, and to immuno- 
histochemical reaction for Leishmania antigens. To 
exclude other etiologic agents, staining by the Ziehl- 
Neelsen and Grocott-Gomori methods was also per- 
formed. 
Drug Regimen 
The patients were treated with itraconazole in capsule 
form for 6 weeks, with a daily dose of 4 mg/kg per day, 
to a maximum of 400 mg per day, administered in two 
daily doses at mealtime. The use of the medication and 
possible side effects were determined every 2 weeks. 
Follow-up 
Patients were followed-up at the outpatient clinic at 15- 
day intervals to determine compliance with treatment 
and the possible occurrence of adverse side effects, such 
as nausea, vomiting, or diarrhea. Hemoglobin, leukocytes, 
and serum transaminases were determined before treat- 
ment and also at 15-day intervals until the end of treat- 
ment. Healing of the mucosal lesions was evaluated by 
otorhinolaryngologic examination, and was considered 
to have occurred when the aforementioned otorhino- 
laryngologic signals had disappeared. These evaluations 
were repeated monthly until the third month after the 
end of treatment. To date, the patients have been fol- 
lowed-up on an ambulatory basis by otorhinolaryngo- 
logic evaluation to ensure early detection of any possible 
recurrence. 
Response to Treatment 
Response to itraconazole treatment was defined as the 
occurrence of healing of MCL lesions within a maximum 
of 12 weeks after the end of treatment, characterized by 
the disappearance of the signs previously described, as 
determined by otorhinolaryngologic examination and by 
the absence of disease reactivation during the follow-up 
period. 
RESULTS 
Patient data concerning age, sex, and clinical, anato- 
mopathologic, and laboratory findings are presented in 
Table 1. No patient presented concomitant cutaneous 
involvement. Ziehl-Neelsen and Grocott-Gomori stains 
were negative in all of them. 
There were no problems concerning tolerance to 
the medication, and no patient abandoned treatment. 
With respect to disease antecedents, two patients were 
hypertensive, one of them taking hydrochlorothiazide 
and the other propanolol. None of the patients took any 
other medications in addition to itraconazole and to the 
antihypertensive drugs taken by these two patients. In 
the otorhinolaryngologic evaluation during the third 
month after the end of treatment, 6 of the 10 patients 
(60%) presented healed lesions with the absence of the 
clinical signs previously described. Two patients previ- 
ously found to be refractory to standard treatment sched- 
ules presented healing after the use of itraconazole. One 
of them had not presented any improvement after the 
use of N-methylglucamine antimoniate and the other one 
had suffered a relapse after the use of pentamidine 
isethionate. The data concerning previous therapeutic 
history and outcome after treatment with itraconazole 
are described in Table 2. To date, the mean follow-up time 
without reactivation of the disease for the patients whose 
lesions were healed by itmconazole has been 14.5 months 
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Table 1. Patient Characteristics Concerning Age, Sex, Clinical, 
Anatomopathologic, and Laboratory Data before Treatment with ltraconazole 
AI-X? Montenegro Serology* 
Patient 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Clinical Examination 
65 Perforation and hyperemia of NS 
48 Granulation and perforation of NS 
63 Perforation and hyperemia of NS 
44 Perforation and hyperemia of NS 
67 Granulation and hyperemia of NS 
40 Granulation and hyperemia of NS and orophatynx 
80 Perforation and hyperemia of NS 
61 Granulation and hyperemia of NS 
44 Perforation and hyperemia of NS 
34 Hyperemia of NS 
Anatomopathologic Examination Reaction (/Fv~ IHR 
Granuloma 
Granuloma 
Granuloma 
Granuloma and presence of amastigote forms 
Chronic infiltrate and intense plasmocytosis 
Chronic infiltrate and intense plasmocytosis 
Chronic infiltrate and intense plasmocytosis 
Chronic infiltrate and plasmocytosis 
Chronic infiltrate and plasmocytosis 
Chronic infiltrate and plasmocflosis + 
+ + + - + - + + ill + + + + + + + - f ND 
*Indirect immunofluorescence reaction (IFI). IHR = immunohistochemical reactton; + = positive; - = negative; ND = not done; NS = nasal septum. 
(range, 12-18 mo). Hematologic parameters and liver 
enzymes monitored during the study were within nor- 
mal values. 
DISCUSSION 
In Brazil, mucocutaneous leishmaniasis, caused by L. viun- 
nia braziliensis, traditionally presents a variable response 
to treatment with antimonials, with frequent relapses.‘* 
Few reports are available in the literature about the spe- 
cific use of itraconazole for treatment of the disease 
caused by L. viannia braziliensis, and no reports exist 
about the use of the drug for treatment of the muco- 
cutaneous forms.15 This report describes the experience 
of 10 patients with MCL treated orally with itraconazole 
on an outpatient basis. 
Studies with antimonials have shown variable eff- 
cacy, some of them reporting a success Tate of about GO%, 
with 30% healing maintained after 12 months of follow- 
UP.~,‘~,~’ Pentamidine and amphotericin B, considered to 
be second-choice treatments, also present variable results, 
at times better than those obtained with antimonials, but 
their toxicity and physiologic difficulties should be con- 
sidered.‘s-20 The same applies to the combination of 
allopurinol and interferon-gamma with antimonials.‘O,” 
Itraconazole has proven action against leishmania in 
vitro, inhibiting important steps in the development of 
the protozoon related to ergosterol synthesis and 
DNA.21,22 The drug presents excellent bioavailability when 
administered orally, especially if ingested with food. By 
being lipophilic, it reaches better tissue concentrations 
than other imidazoles, including concentration in mucosa 
and skin, leading to tissue:blood ratios of up to 3: 1 .23 The 
drug is assumed to reach the skin and mucosa through 
the sebaceous glands and continues to be present in 
active concentrations in these tissues for up to 2 weeks.‘l 
Itraconazole previously has been used for the treatment 
of the cutaneous form of leishmaniasis, also in random- 
ized double blind studies, with a therapeutic success rate 
ranging from 55% to 70%.‘“,‘5,24,25 
In this study, the MCL diagnosis consisted of typical 
otorhinolaryngologic examination, serologic reaction, and 
the anatomopathologic evaluation previously described, 
which are compatible with fmdings in such a disease.26J7 
As previously reported, the presence of leishmanial 
amastigote forms in anatomopathologic evaluation is rare 
in this clinical presentation, and immunohistochemical 
reaction sensitivity ranges from 62% to 70%; consequently, 
its negativity does not exclude a diagnosis of leishmani- 
asis.2”,2R Even when the parasite is not detected by anato- 
mopathologic examination, or when its antigens are not 
Table 2. Therapeutic History and Evolution after Treatment with ltraconazole 
Time Since Previous 
Patient Previous Therapy Therapy (mo) 
1 Antimoniate* 108 
2 None None 
3 None None 
4 None None 
5 None None 
6 None None 
7 Pentamidinet 14 
8 None None 
9 None None 
10 None None 
*N-methylglucamine antimoniate (20 mg/kg/d Sbv for 30 days). 
+Pentamidine isothionate (total dose of 2500 mg). 
Follow-up after 
Response to ltraconazole ltraconazole Treatment (mo) 
Healing 18 
Failure 3 
Failure 3 
Failure 3 
Failure 3 
Healing 14 
Healing 12 
Healing 14 
14 Healing 
Healing 15 
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detected by immunohistochemistry, treatment of MCL 
can be started based on a compatible clinical picture and 
on a positive Montenegro skin test and serology by indi- 
rect immunofluorescence.* In addition, in the present 
study the researchers searched for fungi by Grocott- 
Gomori staining, to rule out the presence of another pas 
sible etiologic agent for which itraconazole could be 
therapeutic, and for mycobacteria by Ziehl-Neelsen stain- 
ing. Both tests were negative in all patients. 
Currently, there are no effective healing or cure cri- 
teria for evaluating MCL treatment, and this may be why 
clinical and otorhinolaryngologic evaluations have been 
used in a large number of studies.4,8,11J9 It is worth 
emphasizing that the presence of an inflammatory 
process, the parasite itself, or its antigens may persist long 
after successful treatment of MCL, as shown by anato- 
mopathologic examination or by immunohistochemistry 
of biopsy material. 26*30 Additionally, serologic tests are of 
questionable usefulness for follow-up after treatment.?l 
On the other hand, L. viunniu braziliensis is a difficult 
parasite to isolate and maintain in the laboratory, so it 
has been difficult to make use of this criterion as evalu- 
ation of treatment success.32x33 
In this study, 6 of the 10 patients treated (60%) pre- 
sented healing of the lesions. Of the six patients who 
evolved with healing of the lesions, two had previously 
used standard treatment schedules, one had not presented 
clinical improvement with a pentavalent antimonial, and 
one had suffered a relapse after healing obtained with 
the use of pentamidine isothionate. The interval between 
treatments (more than 1 y) does not permit the hypoth- 
esis of a favorable response affected by the schedules 
previously used. This fact suggests the possible effec- 
tiveness of itraconazole in patients refractory to other 
treatments. 
Although there are reports in the literature of patients 
who achieved spontaneous MCL healing without any spe- 
cific treatment, this event is unlikely to have occurred in 
the present patients whose lesions healed after itra- 
conazole treatment, since these patients presented active 
disease as determined by otorhinolaryngologic examina- 
tion at the beginning of treatment with this medica- 
tion.4,34 
In the present study there was no apparent differ- 
ence in the therapeutic response of severe cases of the 
disease, considered to be patients with perforation of the 
nasal septum or involvement of the oral mucosa, since the 
lesions healed in four of these six patients, as compared 
to two of four patients with moderate involvement (no 
perforation of the nasal septum). 
The reason that the lesions healed in six patients 
whereas the remainig four patients did not respond to 
itraconazole treatment in this pilot study is unknown; 
also unresolved are questions with respect to treatment 
failure of other medications for MCL, such as pentavalent 
antimonials, drugs that have been used since the late for- 
ties and whose effects have been reported in a much 
larger number of studies on leishmaniasis.35 Theoretically, 
treatment failure could be attributed to factors related to 
the parasite and to host immunity,‘,““J7 It has been 
demonstrated that the therapeutic response depends on 
the leishmanial strain, with L. braziliensis being less sen- 
sitive to pentavalent antimonials than Leishmaniu mex- 
icuna.38 It has also been questioned whether cases of a 
lack of response to antimonials are attributable to the 
resistance of Leishmania or to a deficient host immune 
response, since a Leishmania donovani strain from a 
patient who did not respond to treatment with N-methyl- 
glucamine antimoniate, sodium stibogluconate in com- 
bination with allopurinol, amphotericin B, and 
pentamidine was susceptible in marmosets submitted to 
the same treatment regimen as the patient.39 Future stud- 
ies on itraconazole assessing treatment failure associated 
with parasites resistant to the medication or with 
immunologic parameters of the host would be helpful 
to clarify why some patients with MCL respond to treat- 
ment and others do not. 
In the present study, all the hematologic parameters 
and the hepatic enzymes remained at normal levels, sug- 
gesting that this drug may be useful for patients for whom 
habitual medications are contraindicated. The recurrent 
characteristics of this clinical form require follow-up.‘* 
Over a mean period of 14.5 months (range, 12-18 mo) of 
post-treatment follow-up, no patient presented reactiva- 
tion of the disease. 
The authors have no knowledge of any other study 
on the use of itraconazole for treating MCL; therefore, 
even though this study was conducted on only 10 
patients, it is important for showing the usefulness of 
itraconazole for treatment of MCL. This drug is adminis- 
tered orally and has low toxicity so that it is suitable for 
the epidemiologic reality of MCL in rural and periurban 
areas, contrasting to the high cost and toxicity of standard 
intravenous treatment. The present phase II pilot study 
should be followed by a randomized, double blind con- 
trolled trial to clarify the benefits of itraconazole in MCL. 
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